Brief: Baudax Bio Announces Dosing Of First Cohort In First-In-Man, Phase I Clinical Study Evaluating BX2000
01/06/2022 13:26
June 1 (Reuters) - Baudax Bio Inc BXRX.O :
* BAUDAX BIO ANNOUNCES DOSING OF FIRST COHORT IN
FIRST-IN-MAN,
PHASE I CLINICAL STUDY EVALUATING BX2000
Source text for Eikon: ID:nGNX4x2hKZ
Further company coverage: BXRX.O
Recent news on Baudax Bio
See all newsBrief: Baudax Bio On Feb 22, Filed Voluntary Petition Under Chapter 11 Of U.S. Bankruptcy Code
Brief: Baudax Bio Says Substantial Doubt Exists About Ability To Continue As A Going Concern For Next Twelve Months
Baudax Bio Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Baudax Bio Says Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024
Brief: Baudax Bio Inc - On October 5, 2023, Board Of Directors Of Company Appointed Natalie Mcandrew As Interim Chief Financial Officer